Prostrakan Share Discussion Threads

[azalea] 15/7/2009 10:06

We should get news this month on the launch of Abstral in France and shortly the U.S. patent awarded for Sancuso which in May was achieving sales of 850 patches per week and by end of 2009 reach sales worth GBP £13m.

[azalea] 14/7/2009 15:03

Looking good, the 2x300k trades are a roll over. Whereas the 15:14hrs 300k trade @ 95.44p does look like a buy -not an insignificant purchase. Holding tight!

Edit: judging by the buying the share price should start to roll seriously up hill!.

[azalea] 11/7/2009 10:24

Interesting snippet in Friday's IC-
There are still some promising biotech companies worth paying attention to. PSK now 88p, after we repeated our long standing recc @ 62p, "is one of the few speciality pharmaceutical companies in the UK close to making a profit-and we maintain our positive view".

[azalea] 10/7/2009 09:13

Despite persistant and notable daily net buying volumes, MM are sitting on their hands regarding the sp; I expect this to change after the Interims next month.

[grimraider] 07/7/2009 13:00

Interestingly competitor to Abstral with same dosage and indications launched in Europe by Cephalon - Effentora - buccal vs sub lingual - Cephalon more established and may make growth more more of a challenge

[azalea] 01/7/2009 10:53

MM are taking the micky, 170k net buys yesterday and today(so far) but bid still below 90p.


Edit. 12:17 Can only get a quote for 1k on line.

[grimraider] 18/6/2009 17:27

A blip? or are we on the down again?

[aspers] 05/6/2009 18:24

Happy to hold for a while...that said I bought in at the low and have them stuffed away in my ISA so will come back next year when they are at 300p

[azalea] 05/6/2009 16:40

An almost relentless tick up each day is going to take the share price through 100p next week; albeit a long way to go before it nears brokers' target of 180p+.

[azalea] 04/6/2009 10:18

Just in for 3500x2 @ 90p.

[scotswhaehae] 03/6/2009 11:29

Major up move coming imo...110p plus shortly?

Watch this space!

[the_doctor] 03/6/2009 07:41

Advfn screwing up, but you have news today

[azalea] 27/5/2009 18:35

CEO 14/5/09- "The strength of our performance in the first four months of 2009 reinforces our confidence in achieving our stated target of reaching break even in the closing months of 2009".

Given 2008 FY results Ptx -£25.2, Eps -8.72p, that will be some achievement and anything near to breakeven should see the the share price well north of 100p.

[grimraider] 25/5/2009 17:00

Zulu it would be good if Singer Capital are correct, getting some return on this stock would be a bonus, somewhat long in coming but welcome all the same. However, I have some doubts that current management have the skill to achieve in the current environment

[zulu002] 25/5/2009 12:37

Uk-Analyst: Singer Capital issued a 'buy' note on small pharma company ProStrakan (PSK) citing the company's exciting potential for growth. The shares reacted positively, closing up 0.5p to 84.5p. The broker views the company as a low-risk, speciality company, with increasing revenues based on a highly cash generative portfolio of niche products. The broker believes "A new 82-strong US-based sales and marketing operation will be a key sales contributor." However, despite the growing importance of the US operations the company's European franchise will remain a contributor to sales and earnings growth over the short and medium term, driven by an active sales force and evolving portfolio of products. Singer Capital concluded: "We expect a strong product based news flow over the next 18 months, with sustainable profitability by 2010. We initiate coverage with a Buy recommendation and 173p target price."

[azalea] 23/5/2009 08:33

Unhindered by the the general malaise in international markets, PSK's share price is on the cusp of a significant uprating. A whole stream of buying yesterday could signal its prospects gaining wider recognition.

[zulu002] 22/5/2009 22:21

Business7

Healthy progress for sales at ProStrakan

May 15 2009 Scott Mcculloch

High hopes as revenues soar over first quarter

Prostrakan is predicting it will reach profitability by the end of the year after posting a 40 per cent hike in revenues in the first quarter.

The pharmaceutical company expects to double its European revenues to more than £100million in 2009.

Sales of its breakthrough pain medication Abstral are expected to reach more than £50m with further launches in France and Spain planned in the coming months.

Top-selling product, calcium deficiency treatment Adcal-D3, has grown by 20 per cent in the first three months of the year, despite a 3.9 per cent price decrease following the UK Department of Health's Pharmaceutical Price Regulation Scheme.

Chief executive Dr Wilson Totten said: "ProStrakan has made a really strong start to 2009 both in terms of trading and in further developing the business.

"Product sales are 40 per cent up on last year. Sancuso and Abstral have made very encouraging progress, Fortigel has been submitted for US approval and our development pipeline will result in two further NDAs being filed in the US this year.

"The strength of our performance in the first four months of 2009 reinforces our confidence in achieving our stated target of reaching break even in the closing months of 2009.

"We have also acquired a number of products over the last few years, so the cost base of the company is relatively fixed. So what we are looking to do now is drive sales to the point where we have more income than we have expenditure. The European business, which really drove our growth last year with £56m in total revenues, is still growing very strongly, rising by around 25 per cent again in the first quarter.

"That means in the first quarter, including sales in the US, we have grown by roughly 40 per cent over this time last year, which means we are well on track to become profitable by the end of the year." For the four months from January to the end of April, sales of the company's first commercialised product in the US market, the Sancuso anti-nausea patch, have grown to around 850 a week.

The firm has also increased the number of American sales staff to 82 as it looks to capitalise on the first of its products to be given Food and Drug Administration approval. The company's testosterone replacement therapy, Fortigel, was re-filed in the US last year, and is currently awaiting New Drug Application approval.

ProStrakan will also file NDAs in the US in mid 2009 for pain relief products, Abstral and Cellegesic.

Market analysts predict $400m in US sales for ProStrakan's four products when launched over the next 18 months..

[zulu002] 22/5/2009 22:11

STOCKS NEWS EUROPE-Prostrakan up on bullish update

Shares in Prostakan (PSK.L) climb 3.3 percent after the Scottish speciality pharmaceutical company delivers "an exciting mix of better than anticipated revenues" for the first four months of 2009, according to Numis.

Prostrakan reports a 40 percent sales growth for the first four months of 2009 against the same period in 2008.

"Sales of the group's core products surprised positively, with major pan-European products up 50 percent and even the supposedly maturing AdCal D3 up 20 percent," says Numis in a note.

"With promises kept, everything is on track for ProStrakan to achieve breakeven towards the end of 2009," the broker adds.

[azalea] 19/5/2009 10:15

After the interim management statement, Morgan Stanley in raising the tgt price from 136p to 178p, believes the risk reward is being significantly underestimated. Overall sales raises the Eps forecast of 14p to 21.6p. We view PSK as an emerging speciality pharmaceutical company, rather than a biotech. Reccommends "keep overweight"

PSK could break even this year with blue skies thereafter.

[grimraider] 19/5/2009 09:50

columbo might be of interest SMC advice, less than ideal in own home territory

9.9 sublingual fentanyl 100, 200, 300, 400, 600 and 800mcg sublingual tablets (Abstral) ProStrakan (No. 534/09)

9.9.1 There were no declarations of interest recorded in relation to this product/comparator drugs.

9.9.2 The NDC Chair provided an overview of the assessment, and draft advice. Detailed discussion followed and the group agreed that fentanyl sublingual tablets (Abstral), should be accepted for restricted use in NHS Scotland, for the management of breakthrough pain in adult patients using opioid therapy for chronic cancer pain. Use of sublingual fentanyl tablets should be restricted to patients who are unsuitable for other short-acting opioids e.g. oral morphine. Assessors in liaison with the Secretariat, to make appropriate amendments for review by the Chairman prior to distribution of the advice.

9.9.3 The SMC advice will be issued to NHS Boards and ADTCs on Friday, 09 January 2009.